Biologics

BioPoly looks to raise $5m Series D for joint resurfacing tech

BY 

Schwartz Biomedical subsidiary BioPoly this week registered for a $5 million Series D round for its joint resurfacing technology.

The BioPoly material combines hyaluronic acid, a naturally occurring lubricant found in joint synovial fluid, and ultra-high-molecular-weight polyethylene, a biocompatible polymer. It’s designed to be used during arthroplasty procedures and won CE Mark approval in the European Union in June 2011.

READ THE REST AT MASSDEVICE

Tags

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button